Edwards Lifesciences Issues FY20 Guidance; Affirms 2019 Outlook

(RTTNews) - Edwards Lifesciences Corp. (EW) said, for fiscal 2020, the company estimates adjusted earnings per share in a range of $6.05-6.30. Projected 2020 global sales are $4.5 billion to $5.0 billion; an underlying growth 10-12 percent. Projected 2020 TAVR sales are $2.9 billion to $3.2 billion; an underlying growth 12-15 percent.

Michael Mussallem, CEO, said: "In 2020, we are projecting another year of double-digit top-line and bottom-line growth while we continue to aggressively pursue breakthrough therapies for millions of patients suffering from structural heart diseases."

Also, Edwards Lifesciences reaffirmed its October 2019 financial guidance.